[go: up one dir, main page]

BG103548A - Vitronectine receptor antagonists - Google Patents

Vitronectine receptor antagonists

Info

Publication number
BG103548A
BG103548A BG103548A BG10354899A BG103548A BG 103548 A BG103548 A BG 103548A BG 103548 A BG103548 A BG 103548A BG 10354899 A BG10354899 A BG 10354899A BG 103548 A BG103548 A BG 103548A
Authority
BG
Bulgaria
Prior art keywords
vitronectine
receptor antagonists
antagonists
relates
integrin receptor
Prior art date
Application number
BG103548A
Other languages
Bulgarian (bg)
English (en)
Inventor
William Miller
William Bondinell
Thomas Ku
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of BG103548A publication Critical patent/BG103548A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
BG103548A 1997-01-08 1999-07-01 Vitronectine receptor antagonists BG103548A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3402697P 1997-01-08 1997-01-08
PCT/US1998/000490 WO1998030542A1 (en) 1997-01-08 1998-01-08 Vitronectin receptor antagonists

Publications (1)

Publication Number Publication Date
BG103548A true BG103548A (en) 2000-11-30

Family

ID=21873846

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103548A BG103548A (en) 1997-01-08 1999-07-01 Vitronectine receptor antagonists

Country Status (30)

Country Link
US (2) US6069158A (xx)
EP (1) EP0977735B1 (xx)
JP (1) JP2001508067A (xx)
KR (1) KR20000069941A (xx)
CN (1) CN1249745A (xx)
AP (1) AP9901597A0 (xx)
AR (1) AR010873A1 (xx)
AT (1) ATE235467T1 (xx)
AU (1) AU729641B2 (xx)
BG (1) BG103548A (xx)
BR (1) BR9806852A (xx)
CA (1) CA2276738A1 (xx)
CO (1) CO4920232A1 (xx)
DE (1) DE69812602T2 (xx)
DZ (1) DZ2395A1 (xx)
EA (1) EA199900630A1 (xx)
ES (1) ES2196534T3 (xx)
HU (1) HUP0001945A3 (xx)
ID (1) ID23168A (xx)
IL (1) IL130760A0 (xx)
MA (1) MA26462A1 (xx)
NO (1) NO993350L (xx)
NZ (1) NZ336560A (xx)
OA (1) OA11076A (xx)
PE (1) PE44799A1 (xx)
PL (1) PL334499A1 (xx)
SK (1) SK92799A3 (xx)
TR (1) TR199901575T2 (xx)
WO (1) WO1998030542A1 (xx)
ZA (1) ZA9896B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1027337A4 (en) * 1997-09-04 2002-04-03 Smithkline Beecham Corp Integrin receptor Antagonist
AR015446A1 (es) * 1997-09-19 2001-05-02 Smithkline Beecham Corp Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios
US6576643B2 (en) 1997-09-19 2003-06-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
JP4064059B2 (ja) 1998-04-09 2008-03-19 明治製菓株式会社 インテグリンαVβ3拮抗剤としてのアミノピペリジン誘導体
JP4240424B2 (ja) * 1998-10-23 2009-03-18 エルジー ディスプレイ カンパニー リミテッド エッチング剤及びこれを用いた電子機器用基板の製造方法
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
CA2358855A1 (en) 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
DE19916837A1 (de) * 1999-04-14 2000-10-19 Merck Patent Gmbh Dibenzoazulenderivate
EP1209152A4 (en) 1999-08-05 2003-03-12 Meiji Seika Kaisha OMEGA-AMINO-ALPHA-HYDROXY-CARBONIC ACID DERIVATIVES WITH AN INTEGRIN ALPHA V BETA ANTAGONISM
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002040505A2 (en) * 2000-10-24 2002-05-23 Merck & Co., Inc. Dibenzoxazepine alpha v integrin receptor antagonist
CZ20033119A3 (cs) 2001-04-24 2005-01-12 Merck Patent Gmbh Kombinovaná terapie za použití antiangiogenových činidel a TNF alfa
WO2003059251A2 (en) 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
DK1734996T3 (da) * 2004-04-02 2013-06-10 Univ California Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (xx) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-бензил)-2-фенілбутанаміди як модулятори рецептора андрогену$n-(2-бензил)-2-фенилбутанамиды как модуляторы рецептора андрогена
DE502006004924D1 (de) 2005-05-31 2009-11-05 Ralf Jochem Therapeutsche zusammensetzung zur vorbeugung und bekämpfung von knochenmetastasen
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
EP2335733B1 (en) 2006-01-18 2014-08-06 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
KR20090108713A (ko) 2007-01-18 2009-10-16 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약
BRPI0821090B8 (pt) 2007-12-21 2021-05-25 Ligand Pharm Inc moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
CN102448497A (zh) 2009-05-25 2012-05-09 默克专利有限公司 在癌症治疗中的西仑吉肽的持续给药
AU2010275367B2 (en) 2009-07-24 2015-09-03 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avB5 integrin
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794424A (fr) * 1972-01-24 1973-07-23 Science Union & Cie Nouveaux dibenzocycloheptenes, leur procede d'obtention et leur application comme medicament
US3906032A (en) * 1972-11-10 1975-09-16 Squibb & Sons Inc Dihydroxy-tetrahydronaphthyoxyisobutyric acids and alkyl esters and salts thereof
IT1222986B (it) * 1987-10-23 1990-09-12 Texcontor Ets Derivati dell'efedrina esterificata aventi attivita' antiulcera prolungata nel tempo
US4994463A (en) * 1987-12-14 1991-02-19 Kyowa Hakko Kogyo Co., Ltd. Tricyclic thromboxane A2 antagonists
WO1997001540A1 (en) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists
TR199801254T2 (xx) * 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronektin resept�r� antagonistleri.
US6239138B1 (en) * 1997-07-25 2001-05-29 Smithkline Beecham Corporation Vitronectin receptor antagonist
AR015446A1 (es) * 1997-09-19 2001-05-02 Smithkline Beecham Corp Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios

Also Published As

Publication number Publication date
ES2196534T3 (es) 2003-12-16
CA2276738A1 (en) 1998-07-16
NZ336560A (en) 2000-11-24
ID23168A (id) 2000-03-23
EA199900630A1 (ru) 2000-02-28
AU5912798A (en) 1998-08-03
WO1998030542A1 (en) 1998-07-16
NO993350D0 (no) 1999-07-07
DE69812602D1 (de) 2003-04-30
AP9901597A0 (en) 1999-09-30
CO4920232A1 (es) 2000-05-29
KR20000069941A (ko) 2000-11-25
BR9806852A (pt) 2001-08-07
ZA9896B (en) 1998-10-14
JP2001508067A (ja) 2001-06-19
EP0977735A1 (en) 2000-02-09
MA26462A1 (fr) 2004-12-20
AR010873A1 (es) 2000-07-12
CN1249745A (zh) 2000-04-05
AU729641B2 (en) 2001-02-08
OA11076A (en) 2003-03-13
PE44799A1 (es) 1999-06-10
SK92799A3 (en) 1999-12-10
DZ2395A1 (fr) 2003-06-04
IL130760A0 (en) 2001-01-28
ATE235467T1 (de) 2003-04-15
TR199901575T2 (xx) 1999-11-22
HUP0001945A3 (en) 2001-12-28
EP0977735A4 (en) 2000-04-05
DE69812602T2 (de) 2004-02-19
EP0977735B1 (en) 2003-03-26
US6069158A (en) 2000-05-30
NO993350L (no) 1999-09-06
PL334499A1 (en) 2000-02-28
HUP0001945A2 (hu) 2000-10-28
US6191304B1 (en) 2001-02-20

Similar Documents

Publication Publication Date Title
BG103548A (en) Vitronectine receptor antagonists
MX9805253A (es) Antagonistas del receptor de vitronectina.
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
PT1009732E (pt) 1-amino-alquilciclo-hexanos antagonistas do receptor nmda
WO1999003822A8 (en) Bicyclic metabotropic glutamate receptor ligands
MX9800625A (es) Marcfortinas y paraherquamidas antiparasitarias.
DK0805813T3 (da) Tricyclic vasopressin antagonists
PT1131291E (pt) Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
EP0810994A4 (en) FIBRINOGENIC RECEPTOR ANTAGONISTS
EP0866705A4 (en) FIBRINOGENIC RECEPTOR ANTAGONISTS
BG104916A (en) Calcilytic compounds
ZA989784B (en) Novel cyclopentene derivatives useful as antagonists of the motilin receptor.
ZA9810685B (en) Thrombin receptor antagonists.
HUP0004085A3 (en) Novel 3,6-hemiketals from the class of 9a-azalides
MY133390A (en) Azabicyclic 5ht1 receptor ligands
BR9708347A (pt) Compostos de tetrahidorbeta-carbonila
FI960223A (fi) 1,5-bentsodiatsepiinijohdannaisia, jotka ovat käyttökelpoisia CCK- tai gastriiniantagonisteina
PL335100A1 (en) Oxazolynones as antagonists of 5ht2a receptor
EP0714295A4 (xx)
HK1045684A1 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor.
PL338453A1 (en) 2-acylaminopropanoamines as antagonists of the tachykinin receptor
PL330708A1 (en) Derivatives of indolydine useful as antagonists of 5-ht-2c receptor
AU1296899A (en) Phenyl-alkyl-imidazoles as h3 receptor antagonists
BG103649A (en) Method for the preparation of eprosartan
IL128500A (en) SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b] BENZOFURANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM